Form 6-K NOVO NORDISK A S For: Feb 07
Tweet
Share
E-mailGet inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 7, 2023
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F [X] | Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
| Yes [ ] | No [X] |
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 7 February 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name of the Board | Henrik Ehlers Wulff |
| member/Executive/Associated Person | ||
| 2 | Reason for the notification | |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer | |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| 4 | Details of the transaction(s) | |
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8/ 2023 | |||
| a) | Description of the financial instrument, | Shares | |||
| type of instrument, | |||||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Sale | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 951.9 | 15,000 shares | ||||
| d) | Aggregated information | ||||
| · Aggregated volume | 15,000 Shares | ||||
| · Price | DKK 951.9 | ||||
| e) | Date of the transaction | 2023-02-06 | |||
| f) | Place of the transaction | Nasdaq Copenhagen (XCSE) | |||
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Contact for further information
| Media: | |
Ambre Brown Morley +45 3079 9289 |
Natalia Salomao Abrahao (US) +1 848 304 1027 |
| Investors: | |
Daniel Muusmann Bohsen +45 3075 2175 |
Jacob Martin Wiborg Rode +45 3075 5956 |
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8/ 2023 | |||
|
David Heiberg Landsted +45 3077 6915 |
Mark Joseph Root (US) +1 848 213 3219 |
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 8/ 2023 | |||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 7, 2023 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen Chief Executive Officer |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Reiterates Overweight Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Picket Lines to Go up in the Morning as Carleton University Fails to Address Concerns of Academic Workers
- Dubai to host 'World Biohack Summit'
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
